Streetbeat News

STTK

Shattuck Labs, Inc.

https://www.shattucklabs.com

Industry

Biotechnology

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Open

1.25

Mkt cap

56M

Volume

153K

High

1.26

P/E Ratio

-0.64

52-wk high

11.76

Low

1.18

Div yield

N/A

52-wk low

1.07

Shutterstock's CFO, Jarrod Yahes, is leaving the company to pursue another opportunity. Rik Powell, currently Senior Vice President of Finance and Investor Relations, will take over as CFO on November 1. Yahes will remain in an advisory role until the end of the year.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 1:24 pm

Several healthcare stocks experienced significant price movements during Wednesday's intraday session. Notable gainers included Nuwellis, Streamline Health Solutions, and Inhibikase Therapeutics, while Windtree Therapeutics and Ontrak were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 09, 2024 | 4:31 pm

Several healthcare stocks experienced significant price movements during Tuesday's intraday session. Ontrak, Regional Health Props, Bio-Path Holdings, Portage Biotech, Regencell Bioscience, and Shattuck Labs saw notable gains, while Vincerx Pharma, TransCode Therapeutics, LogicMark, Galecto, Beyond Air, and Instil Bio experienced declines.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:31 pm

Several healthcare stocks experienced significant intraday movements on Wednesday. Notable gainers included Inspire Veterinary, ModivCare, and I-MAB, while Eagle Pharmaceuticals and Windtree Therapeutics were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 4:31 pm

Shattuck Labs shares are experiencing a decline following downgrades from Needham and Citigroup. Needham changed its rating from Buy to Hold, while Citigroup downgraded from Buy to Neutral and reduced the price target from $8 to $2.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 2:37 pm

Citigroup analyst Yigal Nochomovitz has downgraded Shattuck Labs (NASDAQ:STTK) from Buy to Neutral and reduced the price target from $8 to $2.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 1:40 pm

Needham analyst Gil Blum has downgraded Shattuck Labs (NASDAQ:STTK) from Buy to Hold, while maintaining a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 9:41 am

Several healthcare stocks experienced significant price movements during Tuesday's intraday session. Notable gainers included Nuwellis, Sagimet Biosciences, and Opthea, while Gritstone Bio and Applied DNA Sciences were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 4:31 pm

Shattuck Labs (NASDAQ:STTK) is reorganizing its pipeline, discontinuing its SL-172154 cancer program, and laying off 40% of its workforce. The company will focus on developing SL-325 for inflammatory bowel disease. Despite the changes, Shattuck's cash reserves are expected to fund operations until 2027. The stock fell 42.4% following the announcement.

Portfolio Pulse from Vandana Singh

October 01, 2024 | 4:26 pm

HC Wainwright & Co. has downgraded Shattuck Labs (NASDAQ:STTK) from Buy to Neutral, as per analyst Joseph Pantginis.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.